The shares of this global pharmaceutical company surged by approximately 5 percent after the company announced robust financial performance during this financial year. In this article, we will look at the details.
With a market capitalisation of 15,042 crores, the shares of Jubilant Pharmova Ltd are currently trading at Rs 944 per share, down by 28 percent from its 52-week high of Rs 1,309.90 per share. In the last one year, the stock has delivered a return of 33.05 percent.
Financial Highlights
Jubilant Pharmova reported a consolidated revenue of Rs 7,234.5 crores in FY25, up 7.94 percent from Rs 6,702.9 crores in FY24. Additionally, on a year-on-year basis, revenue grew 9.68 percent to Rs 1,928.8 crores in Q4 FY25 from Rs 1,758.6 crores in Q4 FY24. On a quarterly basis, revenue increased by 5.88 percent from Rs 1,821.7 crores.
It reported a net profit of Rs 836.3 crores in FY25, up 1,050.07 percent from Rs 72.7 crores in FY24. Additionally, it turned around to a net profit of Rs 151.3 crores in Q4 FY25 as compared to a loss of Rs 61.8 crores in Q4 FY24. On a quarterly basis, net profit grew by 50.23 percent from Rs 100.7 crores. Additionally, it recommended a dividend of Rs 5 per share on a face value of Rs 1 (500 percent), subject to the approval by the board.
In FY25 revenue, the Radiopharma segment was the highest contributor with Rs 3,388 crore, followed by CDMO – Sterile Injectables with Rs 1,272 crore, CRDMO with Rs 1,151 crore, Allergy Immunotherapy with Rs 701 crore, and Generics with Rs 685 crore. The Proprietary Novel Drugs segment did not contribute to the topline in the year.
About the company
Jubilant Pharmova Limited is a vertically integrated pharmaceutical firm with businesses in India, the Americas, Europe, and worldwide. It has businesses in six verticals, namely Radiopharma for diagnosis and treatment of diseases, Allergy Immunotherapy, Sterile Injectables CDMO, Generics, CRDMO (contract research and manufacturing), and Proprietary Novel Drugs with a focus on oncology and autoimmune treatment. It has clients in pharma, biotech, hospitals, and healthcare industries through a distribution channel that is worldwide.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
